Hematopoietic stem cell transplantation in its 60s: A platform for cellular

Abstract
Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation.
Funding Information
  • Ministero della Salute (PER-2011-2353843 as part of ERA-NET Transcan JTC 2011)
  • Associazione Italiana per la Ricerca sul Cancro (IG 17706)
  • Inca (INCa-Inserm-DGOS SIRIC 6038)
  • ZonMW 4 (ZonMW 43400003 and VIDI-ZonMW 917.11.337)
  • UU (UU 2013-6426, UU 2014-6790 and UU 2015-7601)
  • fp7 transcan (HAPLOIMMUNE)
  • European Commission Transcan (HAPLOIMMUNE)
  • European Commission Transcan (HAPLOIMMUNE)
  • Italian Association for Cancer Research-AIRC (IG 18458)
  • Ministero dell’Istruzione dell’Università e della Ricerca (2015NZWSEC)
  • Deutsche José Carreras Leukämie Stiftung (DJCLS R 15/02DJCLS R 15/02)
  • Dr. Werner Jackstädt Stiftung (Dr. Werner Jackstädt Stiftung)

This publication has 101 references indexed in Scilit: